Küçük Hücre Dışı Akciğer Kanseri Olgularında Serum Vitamin D Düzeyi ve Nivolumab Tedavisinin Etkinliğinin İlişkisi


Özet Görüntüleme: 78 / PDF İndirme: 41

Yazarlar

  • Oktay ÜNSAL Department of Medical Oncology, Gazi University Faculty of Medicine
  • Ozan YAZICI Gazi University Faculty of Medicine

DOI:

https://doi.org/10.5281/zenodo.8402529

Anahtar Kelimeler:

25-hidroksi vitamin D, Nivolumab, Küçük hücre dışı akciğer kanseri

Özet

Amaç: D vitamininin serum düzeyleri ile pozitif yönde orantılı olarak küçük hücre dışı akciğer kanseri (KHDAK) olan hastalarda daha iyi yanıt ve prognoz ile ilişkili olduğu bilinmektedir. Bu yazının amacı, metastatik KHDAK'li hastalarda serum D vitamini seviyeleri ile Nivolumab tedavisinin etkinliği arasındaki ilişkiyi değerlendirmektir.

Gereç ve Yöntem: Metastatik KHDAK tanılı, ikinci basamak tedavide Nivolumab immünoterapisi alan toplam 38 hasta çalışmaya dâhil edildi. Klinik ve demografik veriler ile Nivolumab tedavisine başlamadan önce analiz edilen 25(OH)D düzeyleri kaydedildi. Vitamin D seviyeleri ile progresyonsuz sağkalım (PFS) ve genel sağkalım (OS) arasındaki ilişki analiz edildi. İstatistiksel değerlendirme SPSS 23 kullanılarak yapıldı.

Bulgular: Hastaların ortanca 25(OH)D düzeyi 17.3 (3-37) ng/ml olarak bulundu. Hastaların PFS’leri vitamin D düzeyine göre değerlendirildiğinde, 25(OH)D düzeyi ≥20 ng/ml olan hastaların PFS'si istatistiksel olarak anlamlı olmayan düzeyde diğer gruplara göre daha uzundu (p= 0,17).

Sonuç: Yeterli vitamin D seviyeleri ile daha uzun PFS elde edilmesi, daha yüksek bazal vitamin D seviyelerinin metastatik KHDAK hastalarında daha iyi Nivolumab etkinliği ile ilişkili olduğu gerçeğini destekler.

Referanslar

Akiba, T., Morikawa, T., Odaka, M., Nakada, T., Kamiya, N., Yamashita, M.,… Urashima, M. (2018). Vitamin d supplementation and survival of patients with non-small cell lung cancer: a randomized, double-blind, placebo-controlled trial. Clin Cancer Res an Off J Am Assoc Cancer Res 24(17):4089–4097.

Alsaab, H.O., Sau, S., Alzhrani, R., Tatiparti, K., Bhise, K., Kashaw, S.K., Iyer, A.K. (2017). PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front. Pharm., 8, 561.

Bochen, F., Balensiefer, B., Korner, S., Bittenbring, J.T., Neumann, F., Koch, A.,…Linxweiler, M. (2018). Vitamin D deficiency in head and neck cancer patients-prevalence, prognostic value and impact on immune function. Oncoimmunology, 7, e1476817.

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E.,...Brahmer, J.R. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med; 373: 1627–1639.

Boussiotis V.A. (2016). Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med ; 375:1767–1778.

Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E.,... Spigel, D.R. (2015). Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N. Engl. J. Med. 373, 123–135.

Castellano-Castillo, D., Morcillo, S., Clemente-Postigo, M., Crujeiras, A.B., Fernandez-García, J.C., Torres, E.,… Macias-Gonzalez, M. (2018). Adipose tissue inflammation and VDR expression and methylation in colorectal cancer. Clin Epigenetics 10:60.

Cusato J, Genova C, Tomasello C, Carrega P, Ottonello S, Pietra G,… D’Avolio, A.(2019) Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab. Cancers. 11(1):125.

Dimitrov, V., Bouttier, D., Boukhaled, G., Salehi-Tabar, R., Avramescu, R.G., Memari, B.,...White, J.H. (2017) Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice. J Biol Chem 292(50):20657–20668.

Feng, Q., Zhang, H., Dong, Z., Zhou, Y., Ma, J. (2017). Circulating 25-hydroxyvitamin D and lung cancer risk and survival: A dose-response meta-analysis of prospective cohort studies. Medicine (Baltimore) , 96, e8613.

Gettinger, S., Horn, L., Jackman, D., Spigel, D., Antonia, S., Hellmann, M.,…Brahmer J. (2018). Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol. 36:1675–1684.

Hendrickson, W.K., Flavin, R., Kasperzyk, J.L., Fiorentino, M., Fang, F., Lis, R.,… Giovannucci, E. (2011). Vitamin d receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol Off J Am Soc Clin Oncol. 29(17):2378–2385.

Herbst, R.S., Baas, P., Kim, D-W., Felip, E., Pérez-Gracia, J.L., Han, J-Y.,... Garon, E.B. (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 387; 1540–1550

Khan, M., Lin, J., Liao, G., Tian, Y., Liang, Y., Li, R.,…Yuan, Y. (2018) Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. Medicine (Baltimore), 97, e11936.

Kim, S.H., Chen, G., King, A.N. Jeon, C.K. Christensen, P.J., Zhao, L.,...Ramnath, N. (2012) Characterization of vitamin D receptor (VDR) in lung adenocarcinoma. Lung Cancer 77(2):265–271

Liu, S.Y.M., Zheng, M.M., Pan, Y., Liu, S.Y., Li, Y., Wu, Y.L. (2023). Emerging evidence and treatment paradigm of non-small cell lung cancer. J Hematol Oncol 16, 40.

Menezes, R.J., Cheney, R.T., Husain, A., Tretiakova, M., Loewen, G., Johnson, C.S.,...Reid, M.E. (2008) Vitamin D receptor expression in normal, premalignant, and malignant human lung tissue. Cancer Epidemiol Prev Biomarkers 17(5):1104–1110

Ness, R.A., Miller, D.D., Wei, L. (2015) The role of vitamin D in cancer prevention. Chin J Nat Med 13(7):481–497.

Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A.,…Brahmer JR. (2021). Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol. 39:2339–2349.

Reck, M., Remon, J., Hellman, M.D. (2022). First-line immunotherapy for non–small-cell lung cancer. Journal of Clinical Oncology, 40.6: 586-597.

Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., Pawel, J.v.,…Gandara, D.R. (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255–265.

Ross, A.C., Taylor, C.L., Yaktine, A.L., Valle. H.B.D. eds. Dietary Reference Intakes for Calcium and Vitamin D. National Academies Press (US); 2011. Institute of Medicine. Committee to Review Dietary Reference Intakes for Vitamin D, Calcium. The National Academies Collection: Reports funded by National Institutes of Health.

Samet, J.M., Avila-Tang, E., Boffetta, P., Hannan, L.M., Olivo-Marston, S., Thun, M.J., Rudin, C.M. (2009). Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clinical Cancer Research, 15(18), 5626-5645.

Singh, R.K., Kim, K., Rowswell-Turner, R.B., Hansen, J.N., Khazan, N., Jones, A.,…Moore, R.G. (2020) Targeting Vitamin-D receptor (VDR) by a small molecule antagonist MeTC7 inhibits PD-L1 but controls THMYCN neuroblastoma growth PD-L1 independently. bioRxiv, 2020.08. 16.252940.

Socinski, M.A., Jotte, R.M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N.,...Reck, M. (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301.

Spigel, D.R., Faivre-Finn, C., Gray, J.E., Vicente, D., Planchard, D., Paz-Ares, L.,…Antonia, S.J. (2022). Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 40:1301–1311.

Tykodi, S.S, Schadendorf, D., Cella, D., Reck, M., Harrington, K., Wagner, S., Shaw, J.W. (2018) Patient-reported outcomes with nivolumab in advanced solid cancers. Cancer Treat. Rev., 70, 75–87.

West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H.J.,...Cappuzzo, F. (2019) Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924–937.

You, W., Liu, X., Tang, H., Lu, B., Zhou, Q., Li, Y.,…Tan B. (2023). Vitamin D Status Is Associated With Immune Checkpoint Inhibitor Efficacy and Immune-related Adverse Event Severity in Lung Cancer Patients: A Prospective Cohort Study. Journal of Immunotherapy, 46(6), 236-243.

Zhou, W., Suk, R., Liu, G., Park, S., Neuberg, D.S., Wain, J.C.,… Christiani, D.C. (2005) Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomark Prevent. 14(10):2303–2309.

Zhou, W., Heist, R.S., Liu, G., Asomaning, K., Neuberg, D.S., Hollis, B.W.,… Christiani, D.C. (2007). Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol. 25(5):479–485.

Yayınlanmış

2023-10-04

Nasıl Atıf Yapılır

ÜNSAL, O., & YAZICI, O. (2023). Küçük Hücre Dışı Akciğer Kanseri Olgularında Serum Vitamin D Düzeyi ve Nivolumab Tedavisinin Etkinliğinin İlişkisi. GEVHER NESİBE TIP VE SAĞLIK BİLİMLERİ DERGİSİ, 8(Özel Sayı), 678–684. https://doi.org/10.5281/zenodo.8402529

Sayı

Bölüm

Makaleler